Drug Profile
Research programme: gastrointestinal disorder therapies - Ironwood Pharmaceuticals
Latest Information Update: 20 Aug 2018
Price :
$50
*
At a glance
- Originator Ironwood Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Gastrointestinal disorders
Most Recent Events
- 15 Aug 2018 Depomed is now called Assertio Therapeutics
- 16 Jul 2016 No recent reports of development identified for research development in Gastrointestinal-disorders in USA (PO, Controlled release)
- 28 Jul 2011 Early research in Gastrointestinal disorders in USA (PO)